TRANSITION THERAPEUTICS INC

TORONTO -- Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury .

TORONTO -- Transition Therapeutics Inc. , a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended September 30, 2009.

TORONTO -- Transition Therapeutics Inc. will hold a conference call on Tuesday, November 10, 2009 at 4:30 P.M. EST to discuss First Quarter fiscal 2010 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call.

TORONTO -- Transition Therapeutics Inc. today announced that it has acquired the rights to a series of preclinical compounds from Eli Lilly and Company in the area of diabetes. Under the licensing and collaboration agreement, Transition will receive exclusive worldwide rights to develop and potentially commercialize a class of compounds that, in preclinical diabetes models showed potential to provide glycemic control and other beneficial effects including weight loss.

TORONTO -- Transition Therapeutics Inc. , a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the year ended June 30, 2009.

TORONTO -- Transition Therapeutics Inc. will hold a conference call on Wednesday, September 16, 2009 at 4:30 P.M. EDT to discuss Year-End fiscal 2009 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call.

TORONTO -- Transition Therapeutics Inc. , a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

TORONTO -- Transition Therapeutics Inc. will hold a conference call on Tuesday, May 11, 2010 at 8:30 A.M. EDT to discuss Third Quarter fiscal 2010 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call.

TORONTO -- Transition Therapeutics Inc. announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition, will be presenting at two upcoming conferences: